Xeris Biopharma Shares Rise 13% After Positive Results for Subcutaneous Levothyroxine
marketwatch.com
news
2022-10-20 16:32:00

By Chris Wack Xeris Biopharma Holdings Inc. shares were up 13% to $1.39 after the company said it had positive topline results from its Phase 1 study of subcutaneous levothyroxine in healthy adult volunteers. The stock hit its 52-week low of $1.19 on Monday, and is down 53% year to date. The company said that by using its XeriSol technology, it is developing a novel formulation of levothyroxine sodium injection to potentially mitigate many of the challenges associated with oral formulations of levothyroxine.
